AU2008323853B8 - Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28 - Google Patents

Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28 Download PDF

Info

Publication number
AU2008323853B8
AU2008323853B8 AU2008323853A AU2008323853A AU2008323853B8 AU 2008323853 B8 AU2008323853 B8 AU 2008323853B8 AU 2008323853 A AU2008323853 A AU 2008323853A AU 2008323853 A AU2008323853 A AU 2008323853A AU 2008323853 B8 AU2008323853 B8 AU 2008323853B8
Authority
AU
Australia
Prior art keywords
cells
cell
tumor
cancer
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008323853A
Other languages
English (en)
Other versions
AU2008323853B2 (en
AU2008323853A1 (en
Inventor
David Avigan
Donald Kufe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Beth Israel Deaconess Medical Center Inc
Original Assignee
Dana Farber Cancer Institute Inc
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Beth Israel Deaconess Medical Center Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2008323853A1 publication Critical patent/AU2008323853A1/en
Publication of AU2008323853B2 publication Critical patent/AU2008323853B2/en
Application granted granted Critical
Publication of AU2008323853B8 publication Critical patent/AU2008323853B8/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2008323853A 2007-11-08 2008-11-07 Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28 Ceased AU2008323853B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US253807P 2007-11-08 2007-11-08
US61/002,538 2007-11-08
PCT/US2008/082750 WO2009062001A1 (en) 2007-11-08 2008-11-07 Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28

Publications (3)

Publication Number Publication Date
AU2008323853A1 AU2008323853A1 (en) 2009-05-14
AU2008323853B2 AU2008323853B2 (en) 2014-07-17
AU2008323853B8 true AU2008323853B8 (en) 2014-07-24

Family

ID=40451354

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008323853A Ceased AU2008323853B8 (en) 2007-11-08 2008-11-07 Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28

Country Status (6)

Country Link
US (1) US20100278873A1 (cg-RX-API-DMAC7.html)
EP (2) EP3375868A1 (cg-RX-API-DMAC7.html)
JP (3) JP6230208B2 (cg-RX-API-DMAC7.html)
AU (1) AU2008323853B8 (cg-RX-API-DMAC7.html)
CA (1) CA2704232C (cg-RX-API-DMAC7.html)
WO (1) WO2009062001A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003477B1 (pt) 2011-08-17 2021-11-03 Globeimmune, Inc. Composição imunoterapêutica de muc1 de levedura
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
CN103911341B (zh) * 2014-01-26 2016-04-13 山东迪博生物科技股份有限公司 Th1细胞亚群的制备方法及其在制备抗肿瘤细胞制剂中的应用
JP2017511375A (ja) 2014-03-20 2017-04-20 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 養子細胞療法のための腫瘍浸潤リンパ球
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
US11026921B2 (en) * 2015-03-30 2021-06-08 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
HK1248567A1 (zh) * 2015-03-30 2018-10-19 Dana Farber Cancer Institute, Inc. 治疗急性髓性白血病的组合物和方法
AU2016243192A1 (en) * 2015-03-30 2017-09-07 Beth Israel Deaconess Medical Center Compositions and methods of treating renal cell cancer
US20180267024A1 (en) * 2015-06-08 2018-09-20 Lophius Biosciences Gmbh Composition for determination of cell-mediated immune responsiveness
EP3317403B1 (en) * 2015-06-30 2025-03-05 NorthWest Biotherapeutics, Inc. Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
WO2017151855A1 (en) * 2016-03-03 2017-09-08 Mayo Foundation For Medical Education And Research Materials and methods for increasing immune responses
US20190125848A1 (en) * 2016-03-30 2019-05-02 Dana-Farber Cancer Institute, Inc. Dendritic cell-extracellular vesicle fusions and methods of using same
KR102447145B1 (ko) 2016-03-31 2022-09-23 샌바이오, 인크. 줄기 세포 배양 및 치료를 위한 배지, 방법, 세포 및 분비 인자
CN106434556B (zh) 2016-11-22 2019-10-11 上海新长安生物科技有限公司 一种体外诱导扩增i型nkt细胞的方法
WO2018132559A1 (en) * 2017-01-11 2018-07-19 Dana-Farber Cancer Institute, Inc. Personalized vaccines
CN106834228B (zh) * 2017-01-17 2021-03-23 上海新长安生物科技有限公司 一种体外扩增cd8+t细胞及其细胞亚群的方法
CN116712458A (zh) * 2017-02-07 2023-09-08 学校法人埼玉医科大学 用于预测癌症免疫疗法临床效果的免疫学生物标志物
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
WO2019196087A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
US12442820B2 (en) 2019-02-20 2025-10-14 Saitama Medical University Peripheral blood biomarker for evaluating anti-tumor immune effect of radiation therapy
CN112430575B (zh) * 2019-08-26 2024-01-19 深圳市菲鹏生物治疗股份有限公司 通用型car-t细胞及其制备方法、应用以及抗肿瘤药物
CN111286486A (zh) * 2019-12-19 2020-06-16 清华大学 体外大量扩增恶性肿瘤腹水浸润的淋巴细胞的方法
WO2021186278A1 (en) * 2020-03-20 2021-09-23 Immunitybio, Inc. T cells that respond to patient neoepitopes
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
CN114317445B (zh) * 2020-09-30 2025-07-25 广东东阳光药业股份有限公司 扩增t细胞的方法及其应用
CN112725402A (zh) * 2021-01-22 2021-04-30 华夏源细胞工程集团股份有限公司 一种检测人羊膜上皮细胞体外抑制淋巴细胞增殖抑制方法
EP4319800A1 (en) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
WO2024026505A2 (en) * 2022-07-29 2024-02-01 Amit Patel Disruption of telocyte activity
CN115747159A (zh) * 2022-12-01 2023-03-07 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种用于杀伤肿瘤的肿瘤相关淋巴结t细胞及其制备方法和应用
CN117122675A (zh) * 2023-09-28 2023-11-28 上海恒赛生物科技有限公司 一种用于透明细胞肾细胞癌的树突状细胞疫苗及其应用、制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011715A1 (en) * 1995-09-27 1997-04-03 The Austin Research Institute Mimicking peptides in cancer therapy
WO2007067959A2 (en) * 2005-12-07 2007-06-14 Medarex, Inc. Ctla-4 antibody dosage escalation regimens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
EP0572401B2 (en) 1991-02-19 2007-11-07 The Regents of the University of California Viral particles having altered host range
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US20050170503A1 (en) * 1997-02-27 2005-08-04 University Of Pittsburgh In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
US20020041868A1 (en) * 1997-04-15 2002-04-11 Charles Nicolette Cell fusions and methods of making and using the same
WO2001051608A2 (en) * 2000-01-11 2001-07-19 Greenville Hospital System Hybrid cells obtainable from antigen presenting cells
AU3823601A (en) * 2000-02-11 2001-08-20 Dana Farber Cancer Inst Inc Cytotoxic t lymphocytes activated by dendritic cell hybrids
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6826506B2 (en) 2000-09-18 2004-11-30 Agilent Technologies, Inc. Method and apparatus for calibrating a multiport test system for measurement of a DUT
CN1541113A (zh) * 2001-04-27 2004-10-27 �Ƹ��� 利用激活的t细胞使抗原提呈细胞成熟
CN100528230C (zh) * 2003-02-19 2009-08-19 台桂香 重组人muc1-mbp融合蛋白抗肿瘤疫苗及生产工艺

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011715A1 (en) * 1995-09-27 1997-04-03 The Austin Research Institute Mimicking peptides in cancer therapy
WO2007067959A2 (en) * 2005-12-07 2007-06-14 Medarex, Inc. Ctla-4 antibody dosage escalation regimens

Also Published As

Publication number Publication date
JP2015171389A (ja) 2015-10-01
JP6230208B2 (ja) 2017-11-15
EP3375868A1 (en) 2018-09-19
AU2008323853B2 (en) 2014-07-17
JP2011504101A (ja) 2011-02-03
EP2215220B1 (en) 2018-01-10
EP2215220A1 (en) 2010-08-11
JP2017200486A (ja) 2017-11-09
US20100278873A1 (en) 2010-11-04
CA2704232A1 (en) 2009-05-14
AU2008323853A1 (en) 2009-05-14
CA2704232C (en) 2017-05-02
WO2009062001A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
AU2008323853B8 (en) Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28
JP2011504101A5 (cg-RX-API-DMAC7.html)
AU2016243629B2 (en) Compositions and methods of treating cancer
AU2016243628A1 (en) Compositions and methods of treating cancer
Toujas et al. Human monocyte‐derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I‐restricted exogenous peptides
US20090175890A1 (en) Use of immature dendritic cells to silence antigen specific cd8+ t cell function
CA3012716A1 (en) Dendritic cell-extracellular vesicle fusions and methods of using same
AU2016243626A1 (en) Compositions and methods of treating multiple myeloma
JP5054875B2 (ja) 樹状細胞ハイブリッドによって活性化される細胞傷害性ｔリンパ球
AU2016243194A1 (en) Compositions and methods of treating acute myeloid leukemia
JP2003521936A5 (cg-RX-API-DMAC7.html)
CA3042944A1 (en) Compositions and methods of treating cancer
CA3042945A1 (en) Compositions and methods of treating cancer

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 28 , PAGE(S) 3819 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME BETH ISRAEL DEACONESS MEDICAL CENTER; DANA-FARBER CANCER INSTITUTE APPLICATION NO. 2008323853, UNDER INID (71) CORRECT THE CO-APPLICANT TO DANA-FARBER CANCER INSTITUTE, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired